Search

Your search keyword '"Berrien-Elliott, Melissa"' showing total 347 results

Search Constraints

Start Over You searched for: Author "Berrien-Elliott, Melissa" Remove constraint Author: "Berrien-Elliott, Melissa"
347 results on '"Berrien-Elliott, Melissa"'

Search Results

1. A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy

2. Induced CD8[alpha] identifies human NK cells with enhanced proliferative fitness and modulates NK cell activation

4. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction

6. MicroRNA‐146a deficiency enhances host protection against murine cytomegalovirus.

7. Memory-like differentiation enhances NK cell responses against colorectal cancer.

8. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

10. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant

11. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

15. Anti-myeloma efficacy of BCMA CAR-iNKT is enhanced with a long-acting IL-7, rhIL7hyFc

16. MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells

17. Donor-Derived Memory-like NK Cells for the Treatment of Children and Young Adults with Relapsed AML Following Allo-HCT

18. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

19. Supplementary Figure S7 from Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer

20. Data from Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer

21. Supplementary Table S1 from Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer

22. Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer

26. T-BET and EOMES sustain mature human NK cell identity and antitumor function

27. Brief IL-12, IL-15, IL-18 activation drives the acquisition of two distinct memory-like NK cell states

28. Combined IL-12, IL-15 and IL-18 activation induces epigenetic changes in human NK cells during the memory-like state transition

30. Supplementary Table 5 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy

31. Data from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy

32. Abstract 6418: xWU-NK-101 as salvage therapy post immune checkpoint blockade (ICB)

33. Supplementary Figure Legends from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy

34. Supplementary Table 4 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy

35. Supplementary Figures 1-8 and Tables 1-3 from A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy

36. Data from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

38. Supplementary Tables from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

41. Supplementary Methods from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

45. Supplementary Figures from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

46. Supplementary Figure S4 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

47. Table S1 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

48. Supplementary Table S2 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

49. Figure S3 from Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

50. Data from MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis

Catalog

Books, media, physical & digital resources